Close
  • Home

Archive - August 2020

ADC Digest - August 2020

ADC Digest - August 2020

Antibody–drug conjugates (ADCs)

ADC ‘s are the next generation “targetted” missiles being built in different shapes and forms to attack the enemy in a multitude of ways. What is an ADC – its is a monoclonal antibody tethered to a payload via a chemical linker. They lack the complexity of CAR-Ts, but have their own “improvement” areas. It will be a new weapon in our armamentarium. In the span of 2 weeks we saw both GlaxoSmithKline and AstraZeneca moving ahead with their ADC programs. Read more, tile wise below

Regulatory
The New Drug Application (NDA) for DB-1303/BNT323 for unresectable or metastatic HER2-positive adult breast cancer...
10 April 2026
Regulatory
NextCure receives Fast Track Designation for SIM0505 (CDH6 ADC) in ovarian cancer
10 April 2026
Regulatory
Celltrion ADC drug candidate CT-P71 receives FDA Fast Track Designation for urothelial carcinoma
10 April 2026
Regulatory
Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in second-line HNSCC...
10 April 2026
Regulatory
Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519
3 April 2026
Regulatory
GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan
27 March 2026

Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id